CA
JBIO

Clearstead Advisors’s Jade Biosciences JBIO Stock Holding History

Clearstead Advisors’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$68 Buy
+3
New +$63 ﹤0.01% 3427

Other funds holding JBIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Clearstead Advisors's JBIO Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Jade Biosciences (JBIO) in Q2 2026: 3 shares worth $68. The stake represents ﹤0.01% of the portfolio and ranks #3427 among its holdings.

40 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Clearstead Advisors held 3 shares of Jade Biosciences worth $68 as of Q2 2026.
  • Jade Biosciences was a new Clearstead Advisors position in Q2 2026.
  • Jade Biosciences made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3427 holding.
  • 40 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.